Open Close

CollabRx earnings show improvement over previous year Q2

CollabRx, Inc. (NASDAQ: CLRX) said its total operating revenue for the second quarter of fiscal 2014 was USD251,000, with the entire amount representing the company´s commercialization of its content services and on-line media products.

Revenue for the same quarter of the prior fiscal year was USD75,000.

Gross margins for the quarter were 93% of revenue or USD233,000, compared to 73% of revenue or USD55,000 in the same quarter of the prior fiscal year.

The company´s net loss for the second quarter of fiscal year 2014 was (USD563,000) or (USD0.29) per share, compared with net loss of (USD1,284,000) or (USD0.68) per share for the same period in the prior fiscal year.

Operating expenses totaled USD1,105,000 for the second quarter. Of that amount, USD152,000 were non-cash charges for depreciation, amortization, and stock compensation expense. This represented a decrease in operating expenses from the second quarter of fiscal year 2013, which came in at USD1,347,000 and included USD276,000 of non-cash charges, and an increase from the immediately preceding quarter (Q1FY´14) which came in at USD961,000, including USD143,000 of non-cash charges. The quarter to quarter increase of USD144,000 of operating expenses resulted primarily from increased engineering personnel.

CollabRx is a leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world´s knowledge on genomics-based medicine with specific insights from the nation´s top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at


If you enjoyed this post, please consider leaving a comment or subscribing to the RSS feed to have future articles delivered to your feed reader.